Achillion Pharma Takeout Less Likely After Subpar Hep C Drug Results

Home › Achillion Pharma Takeout Less Likely After Subpar Hep C Drug Results

Tamp down your hopes and dreams if you were expecting Achillion to be the next hepatitis C buyout candidate. Achillion shares are up 18% to $16.84.

04.05	This Week in Agribusiness, May 4, 2024
04.05	Weekly Recap: Sherwin-Williams, BASF, Abrafati Top This Weeks Stories
03.05	'Garden floods show need to work with nature'
03.05	Worst-ever job interviews: 'We had to crawl and moo'
03.05	Have the wheels come off for Tesla?
03.05	BW Converting focuses on time, energy and cost savings at INFOFLEX
03.05	Navigator Paper Ups Offer for Accrual
03.05	USDA urged to restore NASS surveys
More »

je.st